Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Today's Top SOA Links


Basilea reports recruitment completion of phase 3 pivotal study of isavuconazole, an agent for the potential primary treatment of invasive and life-threatening fungal infections

BASEL, SWITZERLAND -- (Marketwire) -- 12/14/12 -- Basilea Pharmaceutica AG / Basilea reports recruitment completion of phase 3 pivotal study of isavuconazole, an agent for the potential primary treatment of invasive and life-threatening fungal infections . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

Basilea Pharmaceutica Ltd. ("Basilea", SIX:BSLN) and its partner Astellas Pharma Inc. ("Astellas") announced today that patient recruitment for the isavuconazole phase 3 registration study SECURE has been completed. Isavuconazole is an investigational intravenous (i. v.) and oral broad-spectrum antifungal being jointly developed by Basilea and Astellas.

The SECURE study is a global double-blind randomized phase 3 study, designed to evaluate the safety and efficacy of once-daily isavuconazole versus twice-daily voriconazole for up to 84 days of therapy in the primary treatment of invasive fungal disease caused by Aspergillus species or other filamentous fungi. Five hundred and twenty-seven (527) patients were enrolled in the study. Acute invasive fungal infections are serious, life-threatening diseases associated with high mortality. The primary endpoint of this non-inferiority study is all-cause mortality through day 42. Basilea and Astellas expect that results of this study will be available in the second half of 2013.

In addition, enrollment into the VITAL study, an open-label phase 3 study of isavuconazole in the treatment of aspergillosis patients with pre-existing renal impairment or patients with invasive fungal disease caused by rare but often fatal molds, yeasts or dimorphic fungi has achieved the targeted recruitment of 100 patients and will continue to recruit to further expand the data base on the use of isavuconazole in the treatment of the diverse rare mold infections. The ACTIVE study, a double-blind randomized phase 3 study evaluating the use of isavuconazole i. v. and oral versus caspofungin i. v. followed by oral voriconazole for the treatment of candidemia and other invasive Candida infections, will likely continue to recruit into 2014.

"Invasive Aspergillus infections cause life-threatening disease in patients undergoing chemotherapy, bone marrow transplantation and other immunocompromised patients. Current pre-clinical and clinical data suggest that isavuconazole may have the potential to overcome certain limitations of current treatment options. We are pleased to have achieved this important milestone together with our partner Astellas, of completing recruitment in the SECURE study, the largest aspergillosis trial ever conducted," said Prof. Achim Kaufhold, Chief Medical Officer at Basilea.

About isavuconazole

Isavuconazole is an investigational intravenous and oral broad-spectrum antifungal. In collaboration with Astellas Pharma Inc., isavuconazole is being investigated in phase 3 clinical studies for the treatment of severe invasive fungal infections. The drug demonstrated excellent in-vitro and in-vivo coverage of a broad range of yeasts (such as Candida species) and molds (such as Aspergillus species) as well as in-vitro activity against less prevalent but often fatal molds such as Mucorales spp. In clinical studies, isavuconazole achieves predictable drug levels allowing reliable dosing and a switch from intravenous administration to a convenient once-daily oral dose.

About Basilea

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX: BSLN). Through the fully integrated research and development operations of its Swiss subsidiary Basilea Pharmaceutica International Ltd. the company focuses on innovative pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology, targeting the medical challenge of rising resistance and non-response to current treatment options.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

This press release can be downloaded from www.basilea.com.

Press release (PDF): http://hugin.info/134390/R/1664857/540108.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Basilea Pharmaceutica AG via Thomson Reuters ONE

[HUG#1664857]

For further information, please contact:

Media Relations
Peer Nils Schroder, Ph.D.
Head Public Relations &
Corporate Communications
+41 61 606 1102
Email Contact

Investor Relations
Barbara Zink, Ph.D., MBA
Head Corporate Development
+41 61 606 1233
Email Contact

About Marketwired .
Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Web 2.0 Latest News
Many projected use cases for IoT won’t directly generate revenues. To achieve greater efficiency, companies are deploying IoT sensors internally throughout their organizations to optimize their use of everything from computer servers to lighting to HVAC systems to employee productivity...
As this year comes to a close, let's take one last look at the most pervasive cloud computing trends -- including increased usage across the different cloud service models, the key business drivers and the impact of agile innovation strategies.

Cloud computing adoption has m...
Cloud computing seems to still be one of the reigning buzzwords in high-tech these days. Everything is either “in the cloud”, “powered by the cloud”, or some variation on the theme. I remember when hosted email was just that: hosted email. Today, such offerings are considered cloud off...
Many workloads are already in the cloud: Most organizations today run at least some workloads in the cloud. For newer organizations, they will often run ALL of their workloads in the cloud. For cloud-based workloads, sending log data to a cloud-based logging provider is not quite as bi...
The book The Cyber Threat was written to provide business and government executives insight into the nature of the dynamic adversaries attacking our networks. Understanding the Cyber Threat is critical to preparing your defenses prior to attack and also instrumental in mounting a de...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE